Search - tctmd.com

Displaying 41 - 60 of 118

Sort: Relevancy | Date

PAD Significantly Ups Morbidity and Mortality in AMICS

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

March 29, 2022

COVID-19: TCTMD’s Dispatch for March Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for March Week 3

March 14, 2022

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

January 20, 2022

Hearts, Lungs, Kidneys: Mild-to-Moderate COVID-19 Leaves a Mark

News Daily News

Hearts, Lungs, Kidneys: Mild-to-Moderate COVID-19 Leaves a Mark

January 14, 2022

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

News Conference News AHA 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

November 18, 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

Long-term Anticoagulation After Unprovoked VTE: New Insights

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

September 13, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

His-bundle Pacing, TAVI Advice Debut in ESC’s Update to Pacing, CRT Guidelines

News Conference News ESC 2021

His-bundle Pacing, TAVI Advice Debut in ESC’s Update to Pacing, CRT Guidelines

September 01, 2021

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

News Daily News

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

August 11, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.